24, 1998, Dura revealed that, due to weak sales of Ceclor CD, Keftab
, Nasarel/Nasalide, Rondec and Dura-Vent, its 1stQ 1998 and 1998 results would be much worse than earlier forecast.
Dura began launching the patented antibiotic Ceclor(R) CD in November and commenced promoting sales of Keftab
The fourth quarter will be Dura's first full quarter marketing Keftab, which is expected to have annual sales of approximately $15 million in 1996.
Besides producing sales growth, the addition of products such as Ceclor CD and Keftab enable Dura to expand its sales force to effectively launch its first Spiros(TM) product (albuterol), expected in late 1998," noted Garner.
Keftab has current annual sales of approximately $15 million.
The addition of Ceclor CD and Keftab complements Dura's existing line of prescription products and is expected to have both strong strategic and positive financial impact.
Dura will begin promoting Keftab to physicians immediately after the transaction closes and will launch and vigorously promote Ceclor CD in time for the upcoming respiratory season.
Meanwhile, the promotion of Ceclor CD and Keftab
by Dura will allow us to concentrate our efforts on maximizing the growth of Prozac(R) and our full complement of new products, including ReoPro(TM), Gemzar(R) and Humalog(R).
Axid (nizatidine, Lilly) Ceclor (cefaclor, Lilly) Gemzar (gemcitabine hydrochloride, Lilly) Humalog (insulin lispro, Lilly) Humulin (human insulin of recombinant DNA origin, Lilly) Humatrope (somatropin of recombinant DNA origin, Lilly) Keftab
(cephalexin hydrochloride, Dista) Keflex (cephalexin, Dista) Lorabid (loracarbef, Lilly) Prozac (fluoxetine hydrochloride, Dista) ReoPro (abciximab), Lilly Vancocin (vancomycin hydrochloride, Lilly)
Bock has marketed Lilly's Keftab
(R), another antibiotic, since 1993, and as part of this current agreement, the term of the Keftab
alliance is being extended.